Varex Imaging(US:VREX)2025-11-18 23:02Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $229 million, an increase of 11% year-over-year, and at the high end of guidance [5][6] - Non-GAAP gross margin for the fourth quarter was 34%, up 130 basis points from the same quarter last year [6][14] - Non-GAAP earnings per share in the fourth quarter was $0.37, up $0.21 compared to last year [6] - For the full fiscal year, total revenue was $845 million, a 4% increase compared to fiscal 2024 [6] - Non-GAAP EBITDA for the year was $122 million, up $33 million from $89 million last year [6] Business Line Data and Key Metrics Changes - Medical segment revenue increased by 5% year-over-year to $152 million in the fourth quarter, while Industrial segment revenue surged by 25% to $77 million [11][12] - For the full year, Medical revenue was $593 million, a 2% increase, and Industrial revenue was $252 million, a 10% increase [6][11] - The Industrial segment achieved its highest revenue quarter ever at $77 million, driven by strong demand for security inspection systems [5][7] Market Data and Key Metrics Changes - Revenue from the Americas grew by 9%, EMEA rose by 16%, and APAC increased by 8% year-over-year [13] - Sales volume to China remained steady, contributing 14% of total revenues, reflecting resilience in the healthcare market despite tariff challenges [13][21] Company Strategy and Development Direction - The company plans to focus on innovation and cost-effectiveness in the value tier and mid-tier segments, particularly in emerging markets like India, South Asia, and Latin America [22][23] - Investments in supply chain and manufacturing regionalization are aimed at strengthening geopolitical resiliency [21][22] - The company is advancing its Photon Counting CT project and expanding production capabilities in India [23][25] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging start to fiscal 2025 due to global tariff situations, but customer ordering patterns have normalized [21] - Expectations for stronger orders and sales in China for 2026 compared to previous years were expressed [21] - The company anticipates gradual growth throughout fiscal 2026, with Medical business expected to grow and Industrial business also projected to increase [41][42] Other Important Information - The company ended the year with $155 million in cash, down from $213 million the previous year, primarily due to debt reduction efforts [6][18] - The company reported a non-cash goodwill impairment charge of $94 million taken in Q3, impacting operating income [14] Q&A Session Summary Question: Can you split the top 10 customers' contribution between Medical and Industrial? - Management indicated that the top 10 customers generally contribute 50%-55% of sales, primarily from the Medical segment, but did not provide a specific breakdown for commercial reasons [30][31] Question: Is there a structural shift in Medical and Industrial segments? - Management noted that Industrial sales are growing and approaching 30% of overall sales, while Medical segment volatility is influenced by geopolitical factors [32][33] Question: Any implications from GE or Siemens Healthineers divesting their China business? - Management stated that the majority of business in China comes from Chinese OEMs, and they do not anticipate significant impacts from these potential divestitures [36][37] Question: Can you provide a high-level outlook for the full year? - Management expects solid demand and growth in both Medical and Industrial segments, with China modeled to be stable [40][41] Question: What is the impact of tariffs on gross margin? - Management indicated that tariffs are impacting gross margin by 100 to 150 basis points, but efforts to reroute supply chains and increase production in India may help mitigate this [81][82]